NIH Researchers to Use Amprion CSF Test in Dementia Biomarker Validation Study

Precision Medicine Online, August 24, 2023

Amprion said on Wednesday that the Center for Alzheimer’s and Related Dementias within the National Institutes of Health’s Intramural Research Program will study levels of misfolded alpha-synuclein proteins in Alzheimer’s disease patients using its biomarker test...READ MORE

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.

Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.